![](https://cdn.myportfolio.com/8d39e44e-cc6f-4fa4-b9c2-2b15145fc8bc/02b0acfc-3eec-45ef-a18b-fe1358f574b4_rw_1920.jpg?h=bd34bcfe3c0976b5b37ac2b822d576c4)
![](https://cdn.myportfolio.com/8d39e44e-cc6f-4fa4-b9c2-2b15145fc8bc/36667811-8d2f-46d4-bb05-1a89761823a3_rw_600.gif?h=b572aa66f9fd62a1f9269b235d54d788)
![](https://cdn.myportfolio.com/8d39e44e-cc6f-4fa4-b9c2-2b15145fc8bc/a6386bd1-1553-4470-a14f-8acc41839497_rw_1200.jpg?h=5667bd3174417eee59f79a5e49479106)
Creative summary
For liquid biopsy analysis, dPCR assays provide a precise, cost-effective, and fast way to monitor response and resistance to treatments by testing for relevant cancer driver and therapy mutations.
Despite being easier to use and less costly than options from the leading supplier, Applied Biosystems™ TaqMan™ dPCR Liquid Biopsy Assays are not top of mind and lag significantly in market share. This campaign aims to change that.
Despite being easier to use and less costly than options from the leading supplier, Applied Biosystems™ TaqMan™ dPCR Liquid Biopsy Assays are not top of mind and lag significantly in market share. This campaign aims to change that.